North Carolina is currently home to 2622 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
04/17/2025
Locations: PMG Research of Charlotte /ID# 217224, Charlotte, North Carolina
Conditions: Endometriosis
Register for Updates
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935
Recruiting
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Carolina BioOncology Institute /ID# 208358, Huntersville, North Carolina
Conditions: Advanced Solid Tumors Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Register for Updates
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/17/2025
Locations: Clinical & Translational Research Center (CTRC), Chapel Hill, North Carolina
Conditions: Ulcerative Colitis
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research at Raleigh Neurology, Raleigh, North Carolina
Conditions: Episodic Migraine
Register for Updates
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
Recruiting
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Colonic Neoplasms
Register for Updates
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310
Recruiting
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Local Institution - 0624, Asheville, North Carolina
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Carteret Medical Group, Morehead City, North Carolina
Conditions: Obesity
Register for Updates
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/16/2025
Locations: Carteret Medical Group, Morehead City, North Carolina
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Register for Updates
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
04/16/2025
Locations: Haywood Pediatric and Adolescent Medicine- Site Number : 8400051, Clyde, North Carolina
Conditions: Pneumococcal Immunization
Register for Updates
Nutrition OUtReach In Systems of Healthcare
NCT06802406
Recruiting
Many children and adults receiving medical treatments have higher costs, which can make it harder for them to afford groceries. When someone can't afford enough food, and they do not receive proper nutrition it can make treatment more difficult. By doing this study investigators hope to learn more about whether addressing food insecurity by giving patients bags of food in clinic can help improve nutrition, reduce costs, and improve transplant and cellular therapy outcomes.
Gender:
ALL
Ages:
Between 8 years and 80 years
Trial Updated:
04/16/2025
Locations: Duke University, Durham, North Carolina
Conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant, CAR-T Cell Therapy, Food Insecurity
Register for Updates
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432
Recruiting
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/16/2025
Locations: Flourish Research, Matthews, North Carolina
Conditions: Alzheimer Disease, Early Onset
Register for Updates